Hosted by Derek van Bever, the two also discuss a number of Steve’s “Kaufmanisms” (for instance, never try to teach a pig to sing good judgment comes from experience and experience comes from bad judgement if you can’t hide it, feature it and culture eats strategy for breakfast every morning!), along with his thoughts on the importance of mentorship, disruptive versus sustaining innovations, his favorite BSSE frameworks, whether incumbents have become better at warding off disruption, and so much more. As such, we wanted to sit down with him to have him to reflect on his career and time working with Clay, his thoughts on the course and its cases, and his forecast for the future of management education. At the end of June, Steve officially retired from the Harvard Business School. Listen to learn more about how Johnson & Johnson has positioned itself to actively look for disruption on the horizon, leading to frequent investments in or partnerships with would-be disruptors, a strategy that has helped to turn perceived threats into tangible opportunities for the future of innovation in healthcare.īack in 2003, Steve Kaufman was the first partner who Clay brought on to teach the BSSE course with him, and he has subsequently had a tremendous impact on generations of our students. Hosted by Innosight's Josh Suskewicz, they discuss The Innovator’s Prescription and how one of the keys to disruption in healthcare is the democratization of products and services enabled by the deskilling of complex medical procedures eliminating disease through prevention, interception, and cure (including why a focus on prevention is so crucial and so challenging) redefining how we think about disease the importance of anchor assets and why the support of leadership at the highest levels is crucial to warding off disruption in incumbent organizations. Hait, who leads a unit comprised of Johnson & Johnson Innovation, the Lung Cancer Initiative at Johnson & Johnson, and the company's World Without Disease Accelerator, oversees the creation of transformational new growth platforms. William Hait, Global Head of Johnson & Johnson External Innovation, discusses how the 135 year old company is using the principles of disruption to improve the trajectory of healthcare across the globe. For instance, can lessons learned on what not to do with online learning help to ignite its adoption going forward? How are teachers thinking about their instructional models in a world rocked by pandemic disruption? How have school systems' RPPs affected their response to the pandemic? And will schools work to reinvent their business models to accommodate changing stakeholder expectations or will K-12 schools remain largely unchanged in the longer term? Listen to this engaging conversation to hear Tom’s thoughts on these important questions and more! In this episode, he joins host Michael Horn to dig into his latest research, sharing insights on what Clay’s frameworks can tell us about recent developments in online learning and also how the incorporation of new techniques in K-12 schooling models might evolve as we slowly emerge from the pandemic. Tom Arnett is Senior Research Fellow – Education at The Clayton Christensen Institute, where he studies instructional models and demand for innovative resources and practices across the K-12 education system. Inspired by Clay’s research, they discuss the role of senior leadership in supporting innovation at large companies the critical insights gained from maintaining a focus on customers’ Jobs To Be Done the challenges and opportunities associated with operating on two tracks, having a strategy both for today and for what’s on the horizon the entrepreneurial mindset successfully capturing value during the scaling process, and more! With attention given to both sides of the innovation coin, this engaging conversation is a must-listen for anyone working to foster innovation within their organizations. In this episode, Christina, who is also a startup mentor and author of The Entrepreneur's BattleBook, joins host Erika Meldrim to reflect on what it takes to advance innovation at both incumbent and startup organizations. In doing so, she draws on her experience having led one of the pharmaceutical industry's first innovation labs, at ViiV Healthcare, along with her time driving innovation, change, and new product commercialization at the pharmaceutical giant, GSK.
In her new role as CEO at Officinae Bio, Christina Nesheva is working to create an inherently innovative organization that pushes the boundaries of nature co-design.